Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy

BACKGROUND: Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Inflamm Bowel Dis
Main Authors: Huang, Vivian W., Prosser, Connie, Kroeker, Karen I., Wang, Haili, Shalapay, Carol, Dhami, Neil, Fedorak, Darryl K., Halloran, Brendan, Dieleman, Levinus A., Goodman, Karen J., Fedorak, Richard N.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2015
Assuntos:
Original Clinical Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4450916/
https://ncbi.nlm.nih.gov/pubmed/25989340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MIB.0000000000000376
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados